Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Cellular Immunotherapy Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the market size of cellular immunotherapy has seen swift expansion. It is projected to rise from $5.72 billion in 2024 to $6.61 billion in 2025, boasting a compound annual growth rate (CAGR) of 15.7%. Factors such as advancements in cancer treatment, clinical achievements, regulatory sanctions, and the escalating prevalence of targeted diseases have all contributed to the growth in the historic period.

What Is the Forecast for the Cellular Immunotherapy Market Size Through 2029?

It is projected that the cellular immunotherapy market will experience rapid expansion in the upcoming years, reaching a value of $11.27 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 14.2%. This growth during the forecast period can be ascribed to factors such as the growth of solid tumors, advancements in manufacturing techniques, improvement of healthcare infrastructure, and increased funding for research. Key trends forecasted for this period include a rise in research and development investments, the availability of clinical trial data, and the use of combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What are the Key Market Players in Cellular Immunotherapy Market and How They’re Evolving?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

What Are the Primary Growth Drivers in the Cellular Immunotherapy Market?

The surge in research activities and successful outcomes of clinical experiments in cellular immunotherapy are projected to fuel the expansion of the cellular immunotherapy market in the foreseeable future. With a targeted focus on creating new cellular immunotherapies for a range of diseases, companies are stepping up their efforts. The Cancer Research Institute, for example, a US-based nonprofit organization exclusively devoted to advancing immunotherapy for the prevention, treatment, and ultimate extermination of all cancers, reported in June 2022 that there were 2,756 active cell therapy drugs in the global immuno-oncology pipeline as of April 2022. This signifies a 36% growth from the 2021 landscape analysis, which listed 2,031 such agents, but also marks a slight drop from the 43% growth in the prior year. The quick-paced progression in the field of cellular immunotherapy at both clinical and preclinical stages in 2020, as compared to 2019, is anticipated to broaden the scope of cellular immunotherapy, leading to increased revenue generation for the cellular immunotherapy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

What Are the Leading Segments in the Global Cellular Immunotherapy Industry?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

What Are the Key Market Trends in the Cellular Immunotherapy Industry?

Firms operating within the cellular immunotherapy market are increasingly focusing on enhancing cancer treatment through the creation of off-the-shelf allogeneic therapies. These therapies are developed from donor cells, unlike autologous treatment that uses the patient’s own cells. The advantages of this approach include cost-efficiency, potential for large-scale production, speedy production, and enhanced quality management. For example, in May 2022, Novartis AG, a Swiss pharmaceutical firm specializing in the research, development, production, and distribution of medications, declared that the US Food and Drug Administration (FDA) has swiftly approved the use of Kymriah (tisagenlecleucel), for adults with relapsed or refractory follicular lymphoma (FL), following at least two lines of systemic therapy. Furthermore, Acepodia, a U.S.-based firm operating in the cell immunotechnology sphere, is set to commence a phase 1 clinical trial in August 2020, to study ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Is the Regional Outlook for the Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

This Report Delivers Insight On:

1. How big is the cellular immunotherapy market, and how is it changing globally?

2. Who are the major companies in the cellular immunotherapy market, and how are they performing?

3. What are the key opportunities and risks in the cellular immunotherapy market right now?

4. Which products or customer segments are growing the most in the cellular immunotherapy market?

5. What factors are helping or slowing down the growth of the cellular immunotherapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model